Search

Your search keyword '"NAKATANI, EIJI"' showing total 396 results
Start Over Author "NAKATANI, EIJI" Language english
396 results on '"NAKATANI, EIJI"'

12. Novel Strategy for the Management of Cervical Multicystic Diseases

Author

Yoshino, Ai, Kobayashi, Eiji, Tsuboyama, Takahiro, Fukui, Hideyuki, Tomiyama, Noriyuki, Sato, Kazuaki, Morii, Eiichi, Nakatani, Eiji, Komura, Naoko, Sawada, Ikuko, Tanaka, Yusuke, Hori, Kensuke, Yoshimura, Akihiko, Takahashi, Ryoko, Iwamiya, Tadashi, Hisa, Tsuyoshi, Nishimura, Sadako, Kitai, Toshihiro, Yokota, Hiromi, Shindo, Mariko, Miyata, Hiromi, Hashimoto, Namiko, Sakiyama, Kanako, Abe, Hazuki, Ueda, Yutaka, and Kimura, Tadashi

Published
2023
Full Text
View/download PDF

17. Longitudinal changes in the prevalence of adult asthma: An epidemiological survey among Japanese salaried employees and their dependents using healthcare insurance claim from 1999 to 2019

Author

Nagayama, Kisako, Fukutomi, Yuma, Nakatani, Eiji, Hamada, Yuto, Irie, Mari, Azekawa, Kazuhiro, Tomita, Yasuhiro, Watai, Kentaro, Kamide, Yosuke, Sekiya, Kiyoshi, Nakamura, Yoichi, Okada, Chiharu, Shimoda, Terufumi, Nagao, Mizuho, Fujisawa, Takao, and Taniguchi, Masami

Published
2023
Full Text
View/download PDF

21. ASO Visual Abstract: Novel Strategy for the Management of Cervical Multicystic Diseases

Author

Yoshino, Ai, Kobayashi, Eiji, Tsuboyama, Takahiro, Fukui, Hideyuki, Tomiyama, Noriyuki, Sato, Kazuaki, Morii, Eiichi, Nakatani, Eiji, Komura, Naoko, Sawada, Ikuko, Tanaka, Yusuke, Hori, Kensuke, Yoshimura, Akihiko, Takahashi, Ryoko, Iwamiya, Tadashi, Hisa, Tsuyoshi, Nishimura, Sadako, Kitai, Toshihiro, Yokota, Hiromi, Shindo, Mariko, Miyata, Hiromi, Hashimoto, Namiko, Sakiyama, Kanako, Abe, Hazuki, Ueda, Yutaka, and Kimura, Tadashi

Published
2023
Full Text
View/download PDF

33. Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients.

Author

Nakatani, Eiji, Ohno, Hiromitsu, Satoh, Tatsunori, Funaki, Daito, Ueki, Chikara, Matsunaga, Taku, Nagahama, Takayoshi, Tonoike, Toru, Yui, Hiromichi, Miyakoshi, Akinori, Tanaka, Yoshihiro, Igarashi, Ataru, Kumamaru, Hiraku, Kuriyama, Nagato, and Sugawara, Akira

Subjects
*CD26 antigen, *TYPE 2 diabetes, *PROPENSITY score matching, *KIDNEY failure, *PERIPHERAL neuropathy
Abstract

Background: Western guidelines often recommend biguanides as the first-line treatment for diabetes. However, dipeptidyl peptidase-4 (DPP-4) inhibitors, alongside biguanides, are increasingly used as the first-line therapy for type 2 diabetes (T2DM) in Japan. However, there have been few studies comparing the effectiveness of biguanides and DPP-4 inhibitors with respect to diabetes-related complications and cardio-cerebrovascular events over the long term, as well as the costs associated. Objective: We aimed to compare the outcomes of patients with T2DM who initiate treatment with a biguanide versus a DPP-4 inhibitor and the long-term costs associated. Methods: We performed a cohort study between 2012 and 2021 using a new-user design and the Shizuoka Kokuho database. Patients were included if they were diagnosed with T2DM. The primary outcome was the incidence of cardio-cerebrovascular events or mortality from the initial month of treatment; and the secondary outcomes were the incidences of related complications (nephropathy, renal failure, retinopathy, and peripheral neuropathy) and the daily cost of the drugs used. Individuals who had experienced prior events during the preceding year were excluded, and events within 6 months of the start of the study period were censored. Propensity score matching was performed to compare between two groups. Results: The matched 1:5 cohort comprised 529 and 2,116 patients who were initially treated with a biguanide or a DPP-4 inhibitor, respectively. Although there were no significant differences in the incidence of cardio-cerebrovascular events or mortality and T2DM-related complications between the two groups (p = 0.139 and p = 0.595), daily biguanide administration was significantly cheaper (mean daily cost for biguanides, 61.1 JPY; for DPP-4 inhibitors, 122.7 JPY; p<0.001). Conclusion: In patients with T2DM who initiate pharmacotherapy, there were no differences in the long-term incidences of cardio-cerebrovascular events or complications associated with biguanide or DPP-4 use, but the former was less costly. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)

Author

Ueno, Hideki, Ishiguro, Megumi, Nakatani, Eiji, Ishikawa, Toshiaki, Uetake, Hiroyuki, Murotani, Kenta, Matsui, Shigeyuki, Teramukai, Satoshi, Sugai, Tamotsu, Ajioka, Yoichi, Maruo, Hirotoshi, Kotaka, Masahito, Tsujie, Masaki, Munemoto, Yoshinori, Yamaguchi, Takashi, Kuroda, Hisashi, Fukunaga, Mutsumi, Tomita, Naohiro, and Sugihara, Kenichi

Published
2021
Full Text
View/download PDF

39. Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center

Author

Masuda, Toshihiro, Nakatani, Eiji, Shirai, Toshihiro, Akamatsu, Taisuke, Tamura, Kanami, Takahashi, Shingo, Tanaka, Yuko, Watanabe, Hirofumi, Endo, Yoshinari, Suzuki, Takahito, Saigusa, Mika, Yamamoto, Akito, Morita, Satoru, Sato, Yoko, and Asada, Kazuhiro

Published
2021
Full Text
View/download PDF

41. Enhancing exercise tolerance in interstitial lung disease with high‐flow nasal cannula oxygen therapy: A randomized crossover trial.

Author

Yanagita, Yorihide, Arizono, Shinichi, Yokomura, Koshi, Ito, Kumiko, Machiguchi, Hikaru, Tawara, Yuichi, Katagiri, Norimasa, Iida, Yuki, Nakatani, Eiji, Tanaka, Takako, and Kozu, Ryo

Subjects
EXERCISE tolerance, NASAL cannula, OXYGEN therapy, INTERSTITIAL lung diseases, CROSSOVER trials, GAS flow
Abstract

Background and Objective: Interstitial lung disease (ILD) is characterized by dyspnoea on exertion and exercise‐induced hypoxaemia. High‐flow nasal cannula (HFNC) therapy reduces the respiratory workload through higher gas flow and oxygen supplementation, which may affect exercise tolerance. This study aimed to examine the effects of oxygen and gas flow rates through HFNC therapy on exercise tolerance in ILD patients. Methods: We conducted three‐treatment crossover study. All ILD patients performed the exercises on room air (ROOM AIR setting: flow, 0 L/min; fraction of inspired oxygen [FiO2], 0.21), HFNC (FLOW setting: flow 40 L/min, FiO2 0.21), and HFNC with oxygen supplementation (FLOW + OXYGEN setting: flow 40 L/min, FiO2 0.6). The primary endpoint was the endurance time, measured using constant‐load cycle ergometry exercise testing at a peak work rate of 80%. Results: Twenty‐five participants (10 men, 71.2 ± 6.7 years) were enrolled. The increase in exercise duration between the ROOM AIR and FLOW was 46.3 s (95% CI, −6.1 to 98.7; p = 0.083), and the FLOW and FLOW + OXYGEN was 91.5 s (39.1–143.9; p < 0.001). The percutaneous oxygen saturation (SpO2) at rest was significantly higher with the FLOW + OXYGEN setting than with the ROOM AIR and FLOW settings, and the difference persisted during exercise. At equivalent time points during exercise, the SpO2 with the FLOW setting was significantly higher than that with the ROOM AIR setting. Conclusion: Oxygen supplementation in HFNC therapy improved exercise tolerance and SpO2. We found that gas flow alone did not improve exercise tolerance, but improved SpO2 during exercise. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer

Author

Kusumoto, Tetsuya, Ishiguro, Megumi, Nakatani, Eiji, Yoshida, Motoki, Inoue, Tsukasa, Nakamoto, Yoshihiko, Shiomi, Akio, Takagane, Akinori, Sunami, Eiji, Shinozaki, Hiroharu, Takii, Yasumasa, Maeda, Atsuyuki, Ojima, Hitoshi, Hashida, Hiroki, Mukaiya, Mitsuhiro, Yokoyama, Tadashi, Nakamura, Masato, Munemoto, Yoshinori, and Sugihara, Kenichi

Published
2018
Full Text
View/download PDF

45. Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)

Author

Ueno, Hideki, Ishiguro, Megumi, Nakatani, Eiji, Ishikawa, Toshiaki, Uetake, Hiroyuki, Matsui, Shigeyuki, Teramukai, Satoshi, Murotani, Kenta, Ajioka, Yoichi, Shimazaki, Hideyuki, Maeda, Atsuyuki, Takuma, Kunio, Yoshida, Takefumi, Kambara, Takeshi, Matsuda, Keiji, Takagane, Akinori, Tomita, Naohiro, and Sugihara, Kenichi

Published
2020
Full Text
View/download PDF

48. The Administration of Lemborexant at Admission is Not Associated with Inpatient Falls: A Multicenter Retrospective Observational Study.

Author

Hirata, Risa, Katsuki, Naoko E, Shimada, Hitomi, Nakatani, Eiji, Shikino, Kiyoshi, Saito, Chihiro, Amari, Kaori, Oda, Yoshimasa, Tokushima, Midori, and Tago, Masaki

Subjects
LOGISTIC regression analysis, SCIENTIFIC observation, HOSPITAL patients, RETROSPECTIVE studies
Abstract

Purpose: There has been no large-scale investigation into the association between the use of lemborexant, suvorexant, and ramelteon and falls in a large population. This study, serving as a pilot investigation, was aimed at examining the relationship between inpatient falls and various prescribed hypnotic medications at admission. Patients and Methods: This study was a sub-analysis of a multicenter retrospective observational study conducted over a period of 3 years. The target population comprised patients aged 20 years or above admitted to eight hospitals, including chronic care, acute care, and tertiary hospitals. We extracted data on the types of hypnotic medications prescribed at admission, including lemborexant, suvorexant, ramelteon, benzodiazepines, Z-drugs, and other hypnotics; the occurrence of inpatient falls during the hospital stay; and patients' background information. To determine the outcome of inpatient falls, items with low collinearity were selected and included as covariates in a forced-entry binary logistic regression analysis. Results: Overall, 150,278 patients were included in the analysis, among whom 3,458 experienced falls. The median age of the entire cohort was 70 years, with men constituting 53.1%. Binary logistic regression analysis revealed that the prescription of lemborexant, suvorexant, and ramelteon at admission was not significantly associated with inpatient falls. Conclusion: The administration of lemborexant, suvorexant, and ramelteon at admission may not be associated with inpatient falls. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Comorbidities associated with 2‐year mortality in adults with cerebral palsy in Japan.

Author

Fujimoto, Yoh, Nakatani, Eiji, and Tabara, Yasuharu

Subjects
*CEREBRAL palsy, *ASPIRATION pneumonia, *PRESSURE ulcers, *ASIANS, *ADULTS
Abstract

Aim: To clarify whether the Whitney Comorbidity Index (WCI) is useful in Asian adults with cerebral palsy (CP) and whether aspiration pneumonia and pressure ulcers improved the prognostic significance of the WCI. Method: This cohort study evaluated individuals aged at least 18 years with CP in Japan. We used Cox proportional hazards regression to analyse 2‐year mortality rates. The predictive performance of the Charlson Comorbidity Index, Elixhauser Comorbidity Index, and WCI were compared as comorbidity assessment criteria. Aspiration pneumonia and pressure ulcers were added to the Cox models, and their impact on hazard ratios was determined. Results: Of the 2232 adults with CP, 72 died during the 2 years. The model with a previously reported weighted WCI with aspiration pneumonia and pressure ulcers produced the best fit. Additionally, the hazard risk of 2‐year mortality for an unweighted WCI score of at least 4 was 2.56; when CP‐specific comorbidities were added, it increased to 8.94. Interpretation: This study showed that the WCI can be used in Asian adults with CP. Furthermore, assessing patient age, aspiration pneumonia, and pressure ulcers in addition to the WCI increased the predictive value for mortality. Our findings indicate that the WCI can promote valid comparisons between international populations. What this paper adds: The Whitney Comorbidity Index (WCI) is useful among adults with cerebral palsy, irrespective of ethnic differences.Assessment of aspiration pneumonia and pressure ulcers increased the WCI predictive value.The WCI helps identify adults with cerebral palsy at risk of adverse outcomes. What this paper adds: The Whitney Comorbidity Index (WCI) is useful among adults with cerebral palsy, irrespective of ethnic differences.Assessment of aspiration pneumonia and pressure ulcers increased the WCI predictive value.The WCI helps identify adults with cerebral palsy at risk of adverse outcomes. This article's abstract has been translated into Japanese. Follow the links from the abstract to view the translations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Prospective study on planned biliary stent placement to treat small common bile duct stones.

Author

Terada, Shuzo, Kawaguchi, Shinya, Nakatani, Eiji, Inagawa, Atsuko, Hikichi, Tomoki, Takeda, Shodai, Ishiguro, Yuya, Kashima, Hirotaka, Hirata, Taiyo, Ikeda, Shinya, Asahara, Kazuhisa, Satoh, Tatsunori, Masui, Yuichi, Matsuda, Masanori, Itai, Ryosuke, Kawai, Asami, Endo, Shinya, Kurokami, Takafumi, Shirane, Naofumi, and Ohno, Kazuya

Subjects
GALLSTONES, ENDOSCOPIC retrograde cholangiopancreatography, CHOLANGIOGRAPHY, ENDOSCOPIC ultrasonography, ASYMPTOMATIC patients, LONGITUDINAL method, CONFIDENCE intervals
Abstract

Aims: Small common bile duct stones are known to occasionally clear spontaneously. This study aimed to prospectively assess the role of biliary stent placement in promoting the spontaneous clearance of small common bile duct stones. Methods and Results: We analyzed patients presenting with common bile duct stones of ≤5 mm diameter between June 2020 and May 2022. The exclusion criteria included asymptomatic patients, biliary pancreatitis, altered gastrointestinal anatomy, bile duct strictures (malignant or benign), and a history of EST. The biliary stents were inserted without stone removal. Stone clearance was assessed using endoscopic ultrasonography or endoscopic retrograde cholangiopancreatography after 3 months. Our primary endpoint was the clearance rate of common bile duct stones over 6 months, targeting a lower limit for the 95% confidence interval (CI) exceeding 25%. Of the 32 enrolled patients, 18 (56.3%; 95% CI: 37.7–73.6%) exhibited stone clearance. Early complications occurred in 11 patients (34.4%), totaling 12 incidents: acute cholecystitis in four, acute pancreatitis in three, biliary pain in three, and cholangitis in two patients. No severe complications occurred. Six (18.8%) patients experienced asymptomatic stent migration. Following stone clearance, four (12.5%) patients experienced stone recurrence, with an average duration of 256 ± 164 days. Conclusion: Biliary stenting appeared to effectively promote the clearance of small common bile duct stones in approximately half of the patients. However, the potential complications and risks of stone recurrence warrant close monitoring. This trial was registered in the Japan Registry of Clinical Trials (jRCT1042200020). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results